Li Lily Wang, PhD

Hematopoietic and Immune Cancer Biology Program
Case Comprehensive Cancer Center

Research Information

Research Interests

My laboratory is currently interested in defining the mechanisms by which immune checkpoint proteins regulate anti-tumor immune responses and to develop rational therapeutics for cancer immunotherapy.

Specifically, we focus on delineating the mechanisms by which a novel immune checkpoint protein, V-domain Immunoglobulin Suppression of T cell Activation (VISTA), modulates immune responses to tumors. My research group has published a series of original research and review articles that address the inhibitory roles of VISTA during the development of anti-tumor immunity, autoimmunity, and inflammatory diseases (1-9). We have shown that VISTA is a critical immune checkpoint protein that controls myeloid cell- and T cell-mediated anti-tumor immunity, therefore is a valuable target for cancer immunotherapy.

Currently, we are committed to discovering novel inhibitory receptors that interact with VISTA and developing effective approaches that block VISTA-mediated immune checkpoint pathway and improve the efficacy of cancer immunotherapy. 

External Appointments

Associate Staff, Translational Hematology and Oncology Research, Cleveland Clinic